Samjin Pharmaceutical

CompanySouth Korea

Samjin Pharmaceutical develops 2 assets, the furthest approved (naloxone hydrochloride in opioid overdose). Mostly small molecule acting on OPRM1, OPRK1 and OPRD1; based in South Korea.

2
Assets
Furthest stage
Approved
3
Trials
19
Signals

Pipeline

2
  • naloxone hydrochloride

    Blocks opioid receptors, reversing opioid-mediated effects.

    Approved, Small molecule, OPRM1, OPRK1, opioid overdose, overdose

  • AR1001

    Inhibits phosphodiesterase 5, increasing cyclic GMP signaling.

    Phase 3, Small molecule, PDE5A, Alzheimer's disease, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Trials10
  • Signals20
  • Similar companies6

Intelligence